Repatha (evolocumab) Revenue
History
| Quarter | Value | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 567M | 50M | +9.67% |
| Mar 31, 2024 | 517M | n/a | n/a |
| Dec 31, 2023 | n/a | n/a | n/a |
| Sep 30, 2023 | n/a | n/a | n/a |
| Jun 30, 2023 | n/a | n/a | n/a |
| Mar 31, 2023 | n/a | n/a | n/a |
| Dec 31, 2022 | n/a | n/a | n/a |
| Sep 30, 2022 | n/a | n/a | n/a |
| Jun 30, 2022 | n/a | n/a | n/a |
| Mar 31, 2022 | n/a | n/a | n/a |
| Dec 31, 2021 | n/a | n/a | n/a |
| Sep 30, 2021 | n/a | n/a | n/a |
| Jun 30, 2021 | n/a | n/a | n/a |
| Mar 31, 2021 | n/a | n/a | n/a |
| Sep 30, 2020 | n/a | n/a | n/a |
| Jun 30, 2020 | n/a | n/a | n/a |
| Mar 31, 2020 | n/a | n/a | n/a |
| Sep 30, 2019 | n/a | n/a | n/a |
| Jun 30, 2019 | n/a | n/a | n/a |
| Mar 31, 2019 | n/a | n/a | n/a |
| Sep 30, 2018 | n/a | n/a | n/a |
| Jun 30, 2018 | n/a | n/a | n/a |
| Mar 31, 2018 | n/a | n/a | n/a |